Preparation of Branched Dextran Microspheres of Soluble Interferon-alpha and its Activity In Vitro and In Vivo |
Hong, Hua
(Department of Medical Genetic Engineering, Keimyung University School of Medicine)
Jo, Jeong-Rang (Department of Medical Genetic Engineering, Keimyung University School of Medicine) Yeon, Ji-Hyeon (Department of Biotechnology, Chungju National University) Hong, Jun-Tack (Department of Food Science and Biotechnology, Joongbu University) Jung, Kyung-Hwan (Department of Biotechnology, Chungju National University) Yoo, Sun-Kyun (Department of Food Science and Biotechnology, Joongbu University) Jang, Byeong-Churl (Department of Medical Genetic Engineering, Keimyung University School of Medicine) |
1 | Jung, K.-H., Y. S. Park, J. H. Yeon, S. H. Kim, S. K. Yoo, and B. C. Jang. 2008. Improving the yield of soluble 6His-tagged interferon- via the addition of repressor of the araBAD promoter system in Escherichia coli. Biotechnol. Lett. 30: 1577-1582. DOI ScienceOn |
2 | Jung, K.-H., Y. J. Lee, J.-H. Yeon, S. K. Yoo, and B.-C. Jang. 2009. Improvement of soluble recombinant interferon- expression by methyl --glucopyranoside in araBAD promoter system of Escherichia coli. Biotechnol. Bioprocess Eng. 14: 274-280. DOI |
3 | Caliceti, P. and F. M. Veronese. 2003. Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. Adv. Drug Deliv. Rev. 55: 1261-1277. DOI ScienceOn |
4 | Franssen, O., L. Vandervennet, P. Roders, and W. E. Hennink. 1999. Degradable dextran hydrogels: Controlled release of a model protein from cylinders and microspheres. J. Control. Release 60: 211-221. DOI ScienceOn |
5 | Fu, K., D. W. Pack, A. M. Klibanov, and R. Langer. 2000. Visual evidence of acidic environment within degrading poly(lactic-co-glycolic acid) (PLGA) microspheres. Pharm. Res. 171: 100-106. |
6 | Goh, K. C., S. J. Haque, and B. R. Williams. 1999. p38 MAP kinase is required for STAT1 serine phosphorylation and transcriptional activation induced by interferons. EMBO J. 18: 5601-5608. DOI |
7 | Heathcote, J. and S. Zeuzem. 2004. Pegylated interferon monotherapy for chronic hepatitis C. Semin. Liver Dis. 24: 39-45. DOI |
8 | Abuchowski, A. A., T. van Es, N. C. Palczuk, and F. F. Davis. 1977. Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. J. Biol. Chem. 252: 3578-3581. |
9 | Beilharz, M. W. 2000. Therapeutic potential for orally administered type 1 interferons. Pharm. Sci. Technol. Today 3: 193-197. DOI ScienceOn |
10 | Chen, F. M., Z. F. Wu, Q. T. Wang, H. Wu, Y. J. Zhang, X. Nie, and Y. Jin. 2005. Preparation of recombinant human bone morphogenetic protein-2 loaded dextran-based microspheres and their characteristics. Acta Pharmacol. Sin. 26: 1093-1103. DOI ScienceOn |
11 | Chourasia, M. K. and S. K. Jain. 2004. Polysaccharides for colon targeted drug delivery. Drug Deliv. 11: 129-148. DOI ScienceOn |
12 | Vyas, S. P., M. Rawat, A. Rawat, S. Mahor, and P. N. Gupta. 2006. Pegylated protein encapsulated multivesiclar liposomes: A novel approach for sustained release of interferon a. Drug Dev. Ind. Pharm. 32: 699-707. DOI ScienceOn |
13 | Shenderova, A., T. G. Burke, and S. P. Schwendeman. 1999. The acidic microclimate in poly(lactide-co-glycolide) microspheres stabilizes camptothecins. Pharm. Res. 16: 241-248. DOI ScienceOn |
14 | Wang, Y. S., S. Youngster, M. Grace, J. Bausch, R. Bordens, and D. F. Wyss. 2002. Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications. Adv. Drug Deliv. Rev. 54: 547-570. DOI ScienceOn |
15 | Kojima, T., M. Hashida, S. Muranishi, and H. J. Sezaki. 1980. Mitomycin C dextran conjugate: A novel high molecular weight pro-drug of mitomycin C. J. Pharm. Pharmacol. 32: 30-34. DOI |
16 | Lee, Y. J. and K.-H. Jung. 2007. Modulation of the tendency towards inclusion body formation of recombinant protein by the addition of glucose in the araBAD promoter system of Escherichia coli. J. Microbiol. Biotechnol. 17: 1898-1903. |
17 | Lim, H. K., S. W. Lee, K. Y. Kang, T. G. Park, and K.-H. Jung. 2002. Sustained release of PEGylated G-CSF from PLGA microsphere. Kor. J. Biotechnol. Bioeng. 17: 33-37. |
18 | Lu, B., J. F. Feng, and X. C. Yang. 2004. Human recombinant interferon-a2a polybutylcyanoacrylate sustained release lyophilized nanospheres for liver-targeting. J. Sichuan Univ. (Med. Sci. Edi.). 35: 1-4. |
19 | Yoshikawa, Y., Y. Komuta, T. Nishihara, Y. Itoh, H. Yoshikawa, and K. Takada. 1999. Preparation and evaluation of once-a-day injectable microspheres of interferon alpha in rats. J. Drug Target. 6: 449-461. DOI ScienceOn |
20 | Vandelli, M. A., F. Rivasi, P. Guerra, F. Forni, and R. Arletti. 2001. Gelatin microspheres crosslinked with -glyceraldehyde as a potential drug delivery system: Preparation, characterisation, in vitro and in vivo studies. Int. J. Pharm. 215: 175-184. DOI ScienceOn |
21 | Matsukawa, Y., S. Nishinarita, T. Horie, M. Moriyama, N. Tanaka, Y. Arakawa, S. Kamei, M. Matsuura, and T. Kojima. 2000. Serum concentration of interferon-alpha: A comparison between once-a-day and twice-a-day administration. Int. J. Clin. Pharmacol. Res. 20: 17-19. |
22 | Matthews, S. J. and C. McCoy. 2004. Peginterferon alfa-2a: A review of approved and investigational uses. Clin. Ther. 26: 991-1025. DOI ScienceOn |
23 | Zhang, Y. M., F. Yang, Y. Q. Yang, F. L. Song, and A. L. Xu. 2008. Recombinant interferon-alpha2b poly(lactic-co-glycolic acid) microspheres: Pharmacokinetics-pharmacodynamics study in rhesus monkeys following intramuscular administration. Acta Pharmacol. Sin. 29: 1370-1375. DOI ScienceOn |
24 | Sanchez, A., M. Tobio, L. Gonzalez, A. Fabra, and M. J. Alonso. 2003. Biodegradable micro- and nanoparticles as longterm delivery vehicles for interferon-alpha. Eur. J. Pharm. Sci. 18: 221-229. DOI ScienceOn |
25 | Shepherd, J., H. Brodin, C. Cave, N. Waugh, A. Price, and J. Gabbay. 2004. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: A systematic review and economic evaluation. Health Technol. Assess. 8: 1-125. |
26 | Neumann, A. U., N. P. Lam, H. Dahari, D. R. Gretch, T. E. Wiley, T. J. Layden, and A. S. Perelson. 1998. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 282: 103-107. DOI ScienceOn |
27 | Yoo, S. K., D. M. Kim, and D. F. Day. 2001. Co-production of dextran and mannitol by Leuconostoc mesenteroides. J. Microbiol. Biotechnol. 11: 880-883. |
28 | Quiroga, J. A., J. Martin, M. Pardo, and V. Carreno. 1994. Serum levels of soluble immune factors and pathogenesis of chronic hepatitis C, and their relation to therapeutic response to interferon-alpha. Dig. Dis. Sci. 39: 2485-2496. DOI ScienceOn |
29 | Roberts, M. J., M. D. Bentley, and J. M. Harris. 2002. Chemistry for peptide and protein PEGylation. Adv. Drug Deliv. Rev. 54: 459-476. DOI ScienceOn |
30 | Schmeisser, H., P. Kontsek, D. Esposito, W. Gillette, G. Schreiber, and K. C. Zoon. 2006. Binding characteristics of IFN-alpha subvariants to IFNAR2-EC and influence of the 6- histidine tag. J. Interferon Cytokine Res. 26: 866-876. DOI ScienceOn |
31 | Mehvar, R. 2000. Dextrans for targeted and sustained delivery of therapeutic and imaging agents. J. Control. Release 69: 1-25. DOI ScienceOn |
32 | Robyt, J. F. and Ecklund, S. H. 1983. Relative, quantitative effect of acceptors in the reaction of Leuconostoc mesenteroides dextransucrase. Carbohydr. Res. 121: 279-286. DOI |
33 | Robyt, J. F. 1986. Encyclopedia of Polymer Science and Technology, pp. 752-767, 4th Ed. John Wiley & Sons, New York, USA. |